ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 569,39
0,13%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) Actualités

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LIFE
DateHeureSourceTitreSymboleSociété
29/05/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
24/05/202422h00GlobeNewswire Inc.aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LIFEaTyr Pharma Inc
24/05/202401h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
15/05/202413h00GlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
14/05/202414h00GlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
06/05/202414h00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
02/05/202422h00GlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/04/202414h00GlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
14/03/202421h00GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
28/02/202414h00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
21/02/202414h00GlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
29/01/202414h00GlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
18/01/202414h00GlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
02/01/202418h21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
21/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
13/11/202314h00GlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
09/11/202323h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
09/11/202322h42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202322h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
09/11/202322h00GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
01/11/202313h00GlobeNewswire Inc.aTyr Pharma to Present at November Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
31/10/202313h00GlobeNewswire Inc.aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDNASDAQ:LIFEaTyr Pharma Inc
11/09/202314h00GlobeNewswire Inc.aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesNASDAQ:LIFEaTyr Pharma Inc
24/08/202314h00GlobeNewswire Inc.aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LIFEaTyr Pharma Inc
10/08/202322h07Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LIFEaTyr Pharma Inc
09/08/202322h00GlobeNewswire Inc.aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
22/06/202314h00GlobeNewswire Inc.European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic SclerosisNASDAQ:LIFEaTyr Pharma Inc
20/06/202314h00GlobeNewswire Inc.aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) ConferenceNASDAQ:LIFEaTyr Pharma Inc
06/06/202314h00GlobeNewswire Inc.aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)NASDAQ:LIFEaTyr Pharma Inc
25/05/202314h00GlobeNewswire Inc.aTyr Pharma to Present at the 2023 Jefferies Healthcare ConferenceNASDAQ:LIFEaTyr Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LIFE

Dernières Valeurs Consultées

LSE
17NJ
Comw.bk.a.31
BIT
P1Z8Y5
NLBNPIT1Z8Y5 20240920 8
TG
H9W
Hwa
LSE
67TY
Investec Bnk 25
TSXV
KEON.H
Keon Capital
BIT
UC3T3P
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés